Let's TalkLet's TalkThe fastest-growing cash-pay category in medicine, and the most heavily restricted to advertise - where the platform rules decide what the campaign can even say.
Weight loss is the most restricted category most clinics will ever advertise in, and the second problem is that patients leave after four months. We will review your creative against the platform rules that actually get accounts restricted, and model your revenue per patient against how long they genuinely stay.
Four failures we see repeatedly in this vertical, and what each one actually costs.
Meta restricts weight loss advertising to adults, prohibits before-and-after imagery, and forbids creative that implies negative self-perception about body image - which rules out most of the language the category instinctively reaches for. Clinics discover this by restriction rather than by reading, usually mid-launch, and lose a month of pipeline recovering the account.
Revenue here is a subscription, and the retention curve falls off sharply once initial results arrive or side effects bite. A clinic that prices acquisition against a twelve-month patient while patients actually stay four is losing money on every enquiry and will not see it for two quarters.
Availability and the regulatory position around compounded formulations have shifted repeatedly, and a campaign promising a specific medication can become unfulfillable in weeks. Creative built around the outcome and the programme survives that; creative built around a drug name does not.
Where the model is telehealth rather than in-person, Google requires LegitScript certification before the ads will run at all. It is an application process, not a setting, and discovering it after a launch date has been promised is the most avoidable delay in this category.
The real deliverables, not a list written to make a proposal look thicker.
Creative against the platform rules, and the retention curve against the price. Either one alone gives a misleading picture of whether the account can work.
Programme, mechanism and clinical supervision instead of body-image framing and results imagery. This is the difference between a campaign that scales and one that gets restricted at the worst moment.
Onboarding, side-effect support and adherence sequences, because acquisition priced against a retention curve you have not improved is buying a shorter patient than the budget assumes.
Positioning built on the programme rather than a named drug, so a supply or regulatory shift does not require a rebuild mid-flight.
Budget follows revenue per retained patient rather than cost per enquiry. In a subscription category that is the only number that tells you whether growth is profitable.
The clinic group below was not a weight loss practice, and we would rather be clear about that than stretch it. The transferable part is the compliance work that kept a multi-state medical account live through expansion, and the conversion moved onto the booked consult - cost per lead down 57% in two weeks, three states to twelve in eighteen months. In a category this heavily restricted, an account that stays live is most of the result.
Read the full case studyOur account was restricted twice before we came here. Nobody had explained that the body-image wording was the problem rather than the photos.
We were pricing acquisition like patients stayed a year. They stayed four months. That one number changed everything.
Building the campaign around the programme instead of the drug name meant we did not have to rebuild when supply changed.
Meta restricts this category to adult audiences, prohibits before-and-after imagery, and forbids creative implying negative self-perception about body image - which excludes most of the language the category reaches for instinctively. Specific outcome promises and pound-figure claims are also constrained. What works instead is the programme, the clinical supervision, the mechanism and who it suits. Written that way from the start, campaigns run; corrected after restrictions, they cost a month.
Because this is a subscription and the retention curve decides whether growth is profitable. Patients commonly leave around month four, once initial results arrive or side effects bite, and a clinic pricing acquisition against a twelve-month patient is losing money on every enquiry without seeing it for two quarters. Improving month four is usually worth more than any reduction in cost per lead.
We would advise against building the campaign on it. Availability and the regulatory position on compounded formulations have shifted repeatedly, and creative built around a named drug can become unfulfillable in weeks - as well as raising claim issues. Positioning on the programme, supervision and outcome survives supply changes and does not need rebuilding mid-flight.
If the delivery model is telehealth, yes - Google requires it before the ads will serve at all, and it is an application process rather than a setting you switch on. In-person clinics generally do not need it. We check this before a campaign is built, because finding out afterwards means a launch date that was never achievable.
No pixel on a patient portal or anything behind a login, no condition or medication names in URLs or forwarded form fields, and conversions sent server-side with personal data hashed before it leaves. This category attracts particular scrutiny because the data is unusually sensitive, and hashing does not excuse collecting something that should never have been sent.
Yes, and the compliance difficulty is the reason. The clinics winning here are the ones whose accounts stay live, and a great many do not - which removes competitors from the auction periodically. Combined with genuine subscription economics, it remains one of the most attractive cash-pay categories in medicine. What it does not tolerate is a generalist agency learning the rules on your account.
This is one part of a bigger service. Here is the whole of it, and the closest neighbours.
No pitch deck, no discovery call you have to sit through. Tell us the situation and we will tell you whether we can help.